Selpercatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-SELPERCATINIB |
|---|---|
| Type | Drug |
| Aliases | RetevmoСелперкатиніб |
| Status | pending_clinical_signoff |
| Diseases | DIS-MTC DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | RET-selective TKI |
|---|---|
| Mechanism | Highly selective RET inhibitor. LIBRETTO-001: ORR ~85% in 1L RET-fusion+ NSCLC. Tumor-agnostic for RET-fusion / RET-mutant cancers (also MTC, papillary thyroid). |
| Typical dosing | 160 mg PO BID (≥50 kg) or 120 mg BID (<50 kg) with food. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
RET-fusion NSCLC 1L+. High response rate transformative for this rare driver.
Used By
Indications
IND-MTC-ADVANCED-1L-SELPERCATINIB- IND-MTC-ADVANCED-1L-SELPERCATINIB
Regimens
REG-SELPERCATINIB-MTC-1L- Selpercatinib monotherapy (advanced/progressive RET-mutant MTC, 1L)REG-SELPERCATINIB-NSCLC- Selpercatinib monotherapy (LIBRETTO-001) — RET fusion+ NSCLC